Skip to main content
Top
Published in: Lung 2/2016

01-04-2016

DIPNECH: Association Between Histopathology and Clinical Presentation

Authors: Rocco Trisolini, Ilaria Valentini, Carmine Tinelli, Marco Ferrari, Gian Marco Guiducci, Sergio Nicola Forti Parri, Giorgia Dalpiaz, Alessandra Cancellieri

Published in: Lung | Issue 2/2016

Login to get access

Abstract

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare disorder which can be an incidental finding in imaging tests performed during the investigation of another condition, or is the final diagnosis in patients evaluated for chronic obstructive complaints. To explore the possible association between specific histopathology features and the mode of clinical presentation, we retrieved the clinical, functional, radiological, and pathological data of all 13 patients diagnosed with DIPNECH at our Institution over a 14-year period (2000–2014). As compared to patients with incidental disease (6/13, 46 %), patients with symptomatic disease were younger [mean (SD): 57.7 vs. 68.7 years, p = 0.046], were more likely to have mosaic attenuation (100 vs. 0 %, p = 0.001) and small multiple nodules (100 vs. 17 %, p = 0.005) at CT, and showed a significantly higher number of foci of linear neuroendocrine proliferation [median (IQR): 28 (13–37) vs. 6 (5–13), p = 0.018] and of tumorlets [median (IQR): 10 (8–20) vs. 1 (1–1), p = 0.002] at histology. Incidental disease was found in association with pulmonary adenocarcinoma in five out of six patients (83.3 %). The results of our study provide preliminary evidence that symptomatic patients with DIPNECH represent a specific subset characterized by younger age and a higher burden of foci of neuroendocrine proliferation.
Literature
1.
go back to reference Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours: pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC Press, Lyon Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours: pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
2.
3.
go back to reference Aguayo SM, Miller YE, Waldron JA Jr et al (1992) Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327:1285–1288CrossRefPubMed Aguayo SM, Miller YE, Waldron JA Jr et al (1992) Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327:1285–1288CrossRefPubMed
4.
go back to reference Miller RR, Muller NL (1995) Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 19:653–658CrossRefPubMed Miller RR, Muller NL (1995) Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 19:653–658CrossRefPubMed
5.
go back to reference Davies SJ, Gosney JR, Hansell DM et al (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62:248–252CrossRefPubMedPubMedCentral Davies SJ, Gosney JR, Hansell DM et al (2007) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 62:248–252CrossRefPubMedPubMedCentral
6.
go back to reference Nassar AA, Jaroszewski DE, Helmers RA et al (2011) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. A systematic overview. Am J Respir Crit Care Med 184:8–16CrossRefPubMed Nassar AA, Jaroszewski DE, Helmers RA et al (2011) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. A systematic overview. Am J Respir Crit Care Med 184:8–16CrossRefPubMed
7.
go back to reference Carr LL, Chung JH, Achcar RD et al (2015) The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest 147:415–422CrossRefPubMed Carr LL, Chung JH, Achcar RD et al (2015) The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest 147:415–422CrossRefPubMed
8.
go back to reference Cohen AJ, King TE, Gilman LB, Magill-Solc C, Miller YE (1998) High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med 158:1593–1599CrossRefPubMed Cohen AJ, King TE, Gilman LB, Magill-Solc C, Miller YE (1998) High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med 158:1593–1599CrossRefPubMed
9.
go back to reference Gorshtein A, Gross DJ, Barak D, Strenov Y, Rafaeli Y, Shimon I, Grozinsky-Glasberg S (2012) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors. Cancer 118:612–619CrossRefPubMed Gorshtein A, Gross DJ, Barak D, Strenov Y, Rafaeli Y, Shimon I, Grozinsky-Glasberg S (2012) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors. Cancer 118:612–619CrossRefPubMed
10.
go back to reference Degan S, Lopez GY, Kevill K, Sunday ME (2008) Gastrin-releasing peptide, immune responses, and lung disease. Ann N Y Acad Sci 1144:136–147CrossRefPubMed Degan S, Lopez GY, Kevill K, Sunday ME (2008) Gastrin-releasing peptide, immune responses, and lung disease. Ann N Y Acad Sci 1144:136–147CrossRefPubMed
11.
go back to reference Impicciatore M, Bertaccini G (1973) The bronchoconstrictor action of the tetra-decapeptide bombesin in the guinea pig. J Pharm Pharmacol 25:872–875CrossRefPubMed Impicciatore M, Bertaccini G (1973) The bronchoconstrictor action of the tetra-decapeptide bombesin in the guinea pig. J Pharm Pharmacol 25:872–875CrossRefPubMed
12.
go back to reference Lach E, Haddad EB, Gies JP (1993) Contractile effect of bombesin on guinea pig lung in vitro: involvement of gastrin-releasing peptide-preferring receptors. Am J Physiol 264:L80–L86PubMed Lach E, Haddad EB, Gies JP (1993) Contractile effect of bombesin on guinea pig lung in vitro: involvement of gastrin-releasing peptide-preferring receptors. Am J Physiol 264:L80–L86PubMed
13.
go back to reference Zhou S, Potts EN, Cuttitta F, Foster WM, Sunday ME (2011) Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma. Proc Natl Acad Sci USA 108:2100–2105CrossRefPubMedPubMedCentral Zhou S, Potts EN, Cuttitta F, Foster WM, Sunday ME (2011) Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma. Proc Natl Acad Sci USA 108:2100–2105CrossRefPubMedPubMedCentral
14.
go back to reference Mireskandari M, Abdiradad A, Zhang Q, Petersen I (2013) Association of small foci of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPENCH) with adenocarcinoma of the lung. Pathol Res Pract 209:578–584CrossRefPubMed Mireskandari M, Abdiradad A, Zhang Q, Petersen I (2013) Association of small foci of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPENCH) with adenocarcinoma of the lung. Pathol Res Pract 209:578–584CrossRefPubMed
15.
go back to reference Warth A, Herpel E, Schmähl A, Storz K, Schnabel PA (2008) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in association with an adenocarcinoma: a case report. J Med Case Rep 2:1–3CrossRef Warth A, Herpel E, Schmähl A, Storz K, Schnabel PA (2008) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in association with an adenocarcinoma: a case report. J Med Case Rep 2:1–3CrossRef
Metadata
Title
DIPNECH: Association Between Histopathology and Clinical Presentation
Authors
Rocco Trisolini
Ilaria Valentini
Carmine Tinelli
Marco Ferrari
Gian Marco Guiducci
Sergio Nicola Forti Parri
Giorgia Dalpiaz
Alessandra Cancellieri
Publication date
01-04-2016
Publisher
Springer US
Published in
Lung / Issue 2/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9854-7

Other articles of this Issue 2/2016

Lung 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.